Reagents and methods for use in cancer diagnosis, classification and therapy

Abstract

Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.

We claim: 
     
         1 . A kit comprising a prognostic panel of antibodies that includes:
 a first antibody that binds to SLC7A5; and   a second antibody that binds to a biomarker selected from the group consisting of p53, NDRG1, HTF9C, and CEACAM5.   
     
     
         2 . The kit of  claim 1 , wherein the second antibody binds to HTF9C. 
     
     
         3 . The kit of  claim 1 , wherein the kit is for prognosis of a breast cancer patient. 
     
     
         4 . The kit of  claim 3 , wherein the breast cancer is estrogen receptor positive (ER+). 
     
     
         5 . The kit of  claim 4 , wherein the breast cancer is node negative (Node−). 
     
     
         6 . The kit of  claim 3 , wherein across a population of breast cancer patients, a higher level of binding of each of the antibodies correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence. 
     
     
         7 . A kit comprising a prognostic panel of antibodies that includes:
 a first antibody that binds to HTF9C; and   a second antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, NDRG1, and CEACAM5.   
     
     
         8 . The kit of  claim 7 , wherein the kit is for prognosis of a breast cancer patient. 
     
     
         9 . The kit of  claim 8 , wherein the breast cancer is estrogen receptor positive (ER+). 
     
     
         10 . The kit of  claim 9 , wherein the breast cancer is node negative (Node−). 
     
     
         11 . The kit of  claim 8 , wherein across a population of breast cancer patients, a higher level of binding of each of the antibodies correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence. 
     
     
         12 . A kit comprising a prognostic panel of antibodies that includes:
 a first antibody that binds to SLC7A5;   a second antibody that binds to HTF9C; and   a third antibody that binds to a biomarker selected from the group consisting of p53, NDRG1, and CEACAM5.   
     
     
         13 . The kit of  claim 12 , wherein the kit is for prognosis of a breast cancer patient. 
     
     
         14 . The kit of  claim 13 , wherein the breast cancer is estrogen receptor positive (ER+). 
     
     
         15 . The kit of  claim 14 , wherein the breast cancer is node negative (Node−). 
     
     
         16 . The kit of  claim 13 , wherein across a population of breast cancer patients, a higher level of binding of each of the antibodies correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence. 
     
     
         17 . A kit comprising a prognostic panel of antibodies that includes:
 a first antibody that binds to SLC7A5;   a second antibody that binds to HTF9C;   a third antibody that binds to p53;   a fourth antibody that binds to NDRG1; and   a fifth antibody that binds to CEACAM5.   
     
     
         18 . The kit of  claim 17 , wherein the kit is for prognosis of a breast cancer patient. 
     
     
         19 . The kit of  claim 18 , wherein the breast cancer is estrogen receptor positive (ER+). 
     
     
         20 . The kit of  claim 19 , wherein the breast cancer is node negative (Node−). 
     
     
         21 . The kit of  claim 18 , wherein across a population of breast cancer patients, a higher level of binding of each of the antibodies correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence. 
     
     
         22 . A kit comprising a prognostic panel of antibodies, the prognostic panel of antibodies consisting essentially of:
 a first antibody that binds to SLC7A5;   a second antibody that binds to HTF9C; and   one, two, or three antibodies that each bind to a different biomarker selected from the group consisting of p53, NDRG1, and CEACAM5.   
     
     
         23 . The kit of  claim 22 , wherein the kit is for prognosis of a breast cancer patient. 
     
     
         24 . The kit of  claim 23 , wherein the breast cancer is estrogen receptor positive (ER+). 
     
     
         25 . The kit of  claim 24 , wherein the breast cancer is node negative (Node−). 
     
     
         26 . The kit of  claim 23 , wherein across a population of breast cancer patients, a higher level of binding of each of the antibodies correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence. 
     
     
         27 . A kit comprising a prognostic panel of antibodies, the prognostic panel of antibodies consisting essentially of:
 a first antibody that binds to SLC7A5;   a second antibody that binds to HTF9C;   a third antibody that binds to p53;   a fourth antibody that binds to NDRG1; and   a fifth antibody that binds to CEACAM5.   
     
     
         28 . The kit of  claim 27 , wherein the kit is for prognosis of a breast cancer patient. 
     
     
         29 . The kit of  claim 28 , wherein the breast cancer is estrogen receptor positive (ER+). 
     
     
         30 . The kit of  claim 29 , wherein the breast cancer is node negative (Node−). 
     
     
         31 . The kit of  claim 28 , wherein across a population of breast cancer patients, a higher level of binding of each of the antibodies correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence.